GnuBIO is a leading developer of scalable DNA sequencing technology for both the Diagnostic and Applied markets. The GnuBIO technology is an emulsion-based microfluidic technology, which provides a scalable desktop sequencing system that allows interrogation of single genes, gene panels, and whole genomes. Using a proprietary DNA sequencing system, the GnuBIO’s platform encompasses all the steps required for DNA sequencing into a single platform including target selection and enrichment, DNA amplification, DNA sequencing and analysis. GnuBIO’s cutting-edge platform provides a single user interface, and a single step process, which rapidly produces results to hours versus days.
Current Team (5)Update
Funding Rounds (4) - $22.5MUpdate
1 Kendall Square
Building 1400, Suite 14201
Cambridge, MA 02139